Recent work associating NSCLC patients carrying co-occurring LKB1 and KRAS mutations with poor prognosis and non-response to immune modulatory drugs highlights a significant unmet need in the lung cancer clinic. This evidence concerns the gene KRAS and non-small cell lung carcinoma.